Study | Primary outcome | |||||
Hr0 | Hr2 | Hr8 | ||||
MD | SE | MD | SE | MD | SE | |
Hughes11 (Travoprost 0.004%/Timolol maleate 0.5%) | 0.3 | 0.351 | 1 | 0.333 | 1.1 | 0.362 |
Schuman14 (Travoprost 0.004%/Timolol maleate 0.5%) | −0.3* | 0.396 | 0.5 | 0.409 | 0.5 | 0.361 |
Diestelhorst9 (Latanoprost 0.005%/Timolol maleate 0.5%) | 0.4 | 0.283 | NR | NR | 0.1 | 0.283 |
Hutzelmann12 (2% Dorzolamide hydrochloride/Timolol maleate 0.5%) | 0 | 0.37 | 0 | 0.37 | NR | NR |
Strohmaier15 (2% Dorzolamide hydrochloride/0.5% Timolol maleate) | 0.5 | 0.433 | −0.1* | 0.472 | 0.6 | 0.471 |
Goñi10 (0.2% Brimonide tartrate/0.5% Timolol maleate) | 0 | 0.698 | 0 | 0.79 | NR | NR |
Konstas13 (0.2% Brimonide tartrate/0.5% Timolol maleate) | NR | NR | 0.2 | 0.684 | NR | NR |
*A negative difference indicates a greater decrease in the intraocular pressure control of the fixed combination.
NR, not recorded.